Brainstorm Cell Therapeutics Inc. (BCLI)
SG&A Expense Growth
106.39%
Quarterly · Period ending:
BCLI SG&A Expense Growth
Latest reported106.39%period ending
Latest reported106.39%period ending
BCLI Quarterly SG&A Growth (QoQ) (0.00% → 106.39%)
Latest values, visible window
High-resolution chart · PNG
BCLI sg&a expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| 106.3863% | |
| 129.275% | |
| -482.0557% | |
| -20.9911% | |
| -18.5994% | |
| 21.7599% | |
| -26.8098% | |
| -2.767% | |
| 36.1533% | |
| -51.2878% | |
| 14.8244% | |
| 1.8832% | |
| 19.2187% | |
| -9.6185% | |
| -19.6085% | |
| 23.6885% | |
| -13.3263% | |
| 12.7811% | |
| 52.8029% | |
| -34.2189% | |
| -2.5502% | |
| -3.1075% | |
| 2.0244% | |
| 53.4584% | |
| -27.7119% | |
| 59.5673% | |
| -4.1478% | |
| 18.419% | |
| -11.481% | |
| -6.6582% | |
| 25.4574% | |
| -21.731% | |
| 20.7519% | |
| 0.0752% | |
| 8.5784% | |
| 91.25% | |
| -22.7986% | |
| 153.5168% | |
| -61.4387% | |
| 1.9231% | |
| 0.7264% | |
| 44.6585% | |
| -46.5356% | |
| 8.0972% | |
| 2.9167% | |
| -6.3415% | |
| 19.4639% | |
| 105.7554% | |
| 18.8034% | |
| -33.3966% | |
| 93.75% | |
| -63.3917% | |
| 32.9159% | |
| 59.2593% | |
| -20.2273% | |
| -1.7857% | |
| -12.1569% | |
| -31.6354% | |
| 32.2695% | |
| -31.9662% | |
| 221.3178% | |
| -59.8131% | |
| 143.1818% | |
| -1.4925% | |
| -27.5676% | |
| -46.0641% | |
| 115.7233% | |
| 1.2739% | |
| 25.0996% | |
| 24.8756% | |
| -50.3704% | |
| -15.4489% | |
| -11.9485% | |
| -40.8696% | |
| 6.3584% | |
| 89.2779% | |
| -38.8883% | |
| -41.463% | |
| 105.7169% | |
| -1.7887% | |
| 0% | |
| 9.9968% | |
| -18.4151% | |
| 29.9254% | |
| 7.9549% | |
| 65.9521% | |
| -80.7761% | |
| 18,003.4031% | |
| -67.9313% | |
| 212.8735% | |
| 69.7142% | |
| -19.3431% | |
| -45.3014% | |
| -1.9478% | |
| 55.2663% | |
| 39.9779% | |
| 0% |